For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Nuvation Bio Inc.

USPTO Granted Patents = 18

% Expired Patents = 27.8

Trademarks = 6

Forward Citations = 29

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

Son Minh Pham (18 out of 26 patents)

Jayakanth Kankanala (16 out of 16 patents)

Sarvajit Chakravarty (12 out of 87 patents)

4. Jiyun Chen (10 out of 10 patents)

5. Jeremy D Pettigrew (8 out of 18 patents)

6. Anjan Kumar Nayak (7 out of 11 patents)

7. Anup Barde (7 out of 7 patents)

8. Brahmam Pujala (6 out of 22 patents)

9. Anil Kumar Agarwal (5 out of 9 patents)

10. David Hung (5 out of 5 patents)

11. Sreekanth A Ramachandran (4 out of 8 patents)

12. Sanjeev Soni (4 out of 4 patents)

13. Pradeep S Jadhavar (4 out of 4 patents)

14. Farha Khan (4 out of 4 patents)

15. Deepak Palve (3 out of 3 patents)

18 patents: Sort by Forward Citations

1. 12398121 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-08-26),

2. 12208141 - Anti-cancer nuclear hormone receptor-targeting compounds (2025-01-28),

3. 12006314 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-06-11),

4. 11952349 - Anti-cancer nuclear hormone receptor-targeting compounds (2024-04-09),

5. 11834458 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-12-05),

6. 11826430 - Anti-cancer nuclear hormone receptor-targeting compounds (2023-11-28),

7. 11584756 - Heterocyclic compounds as BET inhibitors (2023-02-21),

8. 11332473 - Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors (2022-05-17),

9. 11306071 - Heterocyclic compounds as adenosine antagonists (2022-04-19),

10. 11299493 - Heterocyclic compounds and uses thereof (2022-04-12),

11. 11292782 - Diarylhydantoin compounds and methods of use thereof (2022-04-05),

12. 11254670 - 1,8-naphthyridinone compounds and uses thereof (2022-02-22),

13. 11192900 - Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors (2021-12-07),

14. 11174252 - Heterocyclic compounds as kinase inhibitors (2021-11-16),

15. 11034669 - Pyrrole and pyrazole compounds and methods of use thereof (2021-06-15),

Company Overview

Nuvation Bio Inc. is a biotechnology company based in New York, specializing in the development of innovative therapies for cancer treatment. The organization focuses on harnessing advanced scientific research to create novel drug candidates that target specific cancer pathways. With a commitment to addressing unmet medical needs, Nuvation Bio employs cutting-edge technology and a robust research framework to advance its pipeline of potential therapeutics, aiming to improve patient outcomes in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

18 Patents

#435 in New York, NY

#1,054 in New York

#17,974 in US

#34,244 in the World

New York, NY, United States of America

Nuvation Bio Inc.

Forward Citations = 29

28 inventors:

Son Minh Pham (18 out of 26 patents)

Jayakanth Kankanala (16 out of 16 patents)

Sarvajit Chakravarty (12 out of 87 patents)

4. Jiyun Chen (10 out of 10 patents)

5. Jeremy D Pettigrew (8 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nuvation Bio Inc.. Retrieved from https://idiyas.com/company/nuvation-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…